Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05XEA
|
|||
| Former ID |
DNCL003132
|
|||
| Drug Name |
RP5063
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 2 | [1] | |
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [2] | ||
| Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Phase 1 | [2] | ||
| Bipolar disorder [ICD-11: 6A60; ICD-10: F31] | Phase 1 | [2] | ||
| Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Phase 1 | [2] | ||
| Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 1 | [2] | ||
| Company |
Reviva Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01490086) RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271 | |||
| REF 4 | EFFICACY AND SAFETY OF NOVEL DOPAMINE SEROTONIN STABILIZER RP 5063 IN ACUTE SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER. Schizophrenia Research Volume 153, Supplement 1, April 2014, Pages S22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.